Telapristone acetate

Synonyms: CDB-4124
Telapristone acetate (CDB-4124) 是一种强效的孕激素受体 (PR) 调节剂,通过诱导细胞周期阻滞和凋亡 (apoptosis) 抑制卵巢癌细胞增殖,并能有效抑制大鼠自发性及化学诱导性乳腺肿瘤的发生和发展,可用于乳腺癌和卵巢癌的研究。
产品编号: MS-G51126 CAS No.: 198414-31-2 分子式: C31H39NO5 分子量: 505.65
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价

产品描述

Telapristone acetate (CDB-4124) 是一种强效的孕激素受体 (PR) 调节剂,通过诱导细胞周期阻滞和凋亡 (apoptosis) 抑制卵巢癌细胞增殖,并能有效抑制大鼠自发性及化学诱导性乳腺肿瘤的发生和发展,可用于乳腺癌和卵巢癌的研究。

生物实验数据

生物活性 Telapristone acetate (CDB-4124) is a potent progesterone receptor (PR) modulator that inhibits ovarian cancer cell proliferation by inducing cell cycle arrest and apoptosis, effectively suppresses the occurrence and development of spontaneous and chemically induced mammary tumors in rats, and can be used for research on breast cancer and ovarian cancer.
IC50 & Target

IC50:35.5±3.9,21.3±1.8,43.6±5.1,47.4±3.9 μM of IGROV-1, IGROV-1 PTES, SKOV-3, SKOV-3 PTES cells, respectively.

体外研究
(In Vitro)

Telapristone acetate (0-60 μM,96 小时) 可抑制对 Cisplatin (CDDP) (MS-E94993) 和 Paclitaxel (PTX) (HY-B0015) 耐药的卵巢癌细胞的生长,其 IC50 值分别为 35.5 μM (IGROV-1)、21.3 μM (IGROV-1 PTES)、43.6 μM (SKOV-3) 和 47.4 μM (SKOV-3 PTES)。
Telapristone acetate (30 μM,48 小时) 可诱导 IGROV-1 和 IGROV-1 PTES 细胞发生细胞周期阻滞和凋亡,分别表现为 p21Cip1/p27Kip1 的上调和 PARP 裂解。
Telapristone acetate (0-10 μmol/L,3-6 天) 可诱导 G1/S 细胞周期停滞,从而通过下调人 T47D 细胞中的 CDK2 和 CDK4 来抑制细胞生长。

Western Blot Analysis

Cell Line: human T47D cells
Concentration: 1 μmol/L
Incubation Time: 3 and 6 days
Result: Failed to affect the expression of PRA,PRB, cyclin D1, or CDK6.
Decreased ERα expression.
Decreased CDK2 and CDK4 expressions.

Cell Viability Assay

Cell Line: IGROV-1, IGROV-1 PTES, SKOV-3, and SKOV-3 PTES
Concentration: 0, 7.5, 15, 30 and 60 μM
Incubation Time: 96 h
Result: Reduced the viability of IGROV-1, IGROV-1 PTES, SKOV-3, and SKOV-3 PTES cells in a dose-dependent manner.

Western Blot Analysis

Cell Line: IGROV-1 and IGROV-1 PTES
Concentration: 30 μM
Incubation Time: 48 h
Result: Caused an increase in the abundance of the cell cycle inhibitor p27kip1 in both parental and PTES cells.
Increased cyclin dependent kinase inhibitor p21cip1, cell cycle arrest associated protein.
Showed no significant differences in the expression of G1 regulatory proteins CDk2 and cyclin E between parental and PTES cells.
Induced the cleavage of PARP, indicating it induces cell apopotosis.

Cell Proliferation Assay

Cell Line: human T47D cells
Concentration: 0, 0.1, 1.0 and 10 μmol/L
Incubation Time: 3 and 6 days
Result: Did not affect cell growth after either 3 days or 6 days of treatment at 0.1 μmol/L.
Suppressed cell growth in a dose-dependent manner at 1.0 and 10 μmol/L.

Cell Cycle Analysis

Cell Line: human T47D cells
Concentration: 0.1, 1.0 and 10 μmol/L
Incubation Time: 3 and 6 days
Result: Decreased the percentage of cells in S phase from 12.2% (control) to 8.5% after 3 days.
Decreased the percentage of cells in S phase from 14.1% (control) to 9.3% after 6 days.
Significant increased the proportion of cells in the G1/G0 phase after 6 days.
Inhibited the transition of cells from G1 to S phase of the cell cycle.
体内研究
(In Vivo)

Telapristone acetate (20、70 和 200 mg/kg,每日灌胃,持续 24 个月) 通过减少小叶增生和良性肿瘤的发生来抑制大鼠的自发性乳腺癌发生。
Telapristone acetate (3 和 30 mg/颗粒,皮下注射,持续 84 天,于 MNU 注射后 6 天开始) 能抑制大鼠癌前病变和致癌物诱导的 ER 阳性乳腺肿瘤的发展。

Animal Model: Female SD rats
Dosage: 20, 70, and 200 mg/kg
Administration: i.g., daily for 24 months
Result: Showed no significant changes at 20 and 70 mg/kg doses.
Slightly decreased the body weight (12.5%) at 200 mg/kg but the difference with control group was not significant.
Exhibited no substantial differences in tumors or other pathologies in internal organs (liver, spleen, heart, lung, intestine, brain, kidneys), compared to control.
Decreased fibroadenomas and hyperplastic lesions with atypia.
Increase cystic formations and induced calcifications among mammary gland parenchyma.
Reduced ductal lateral branching that leads to reduction in lobular structures in mammary gland.
Animal Model: Female SD rats (50 days old) intraperitoneally injected with N-methyl-N-nitrosourea (MNU)
Dosage: 3.0 and 30.0 mg/pellet
Administration: s.c., over 84 days, initiated 6 days post-MNU
Result: Significantly decreased the percentage of Ki-67-positive cells from 16.5% (control) to 9.1%.
Suppressed cell proliferation and induces apoptosis.
Showed average tumor latency of 74 days for the low-dose and 87 days for the high-dose.
Suppressed the incidence and multiplicity of mammary tumors in a dose-dependent manner.
Decreased tumor incidence from 85% (control) to 60% (low dose) and 35% (high dose).
Decreased tumor multiplicity, from 3.0 tumors/rat in the control group to 2.2 and 1.1 tumors/rat in the low- and high-dose, respectively.
Resulted in an increase in intercellular spaces between tumor cells and the development of cystic formations. Decreased serum progesterone, but had no effect on estradiol.
Suppressed PR expression in mammary tumors.
Showed no significant changes in animal body weight.

化学信息

分子量 505.65
分子式 C31H39NO5
CAS No. 198414-31-2
别名 CDB-4124

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础